Table 2.

Study 1: change in pharmacodynamic variables

Variable	1,000 mg Met IR twice-daily (n = 19)	1,000 mg Met DR twice-daily (n = 19)	500 mg Met DR twice-daily (n = 19)
FPG, mmol/l
Baseline	11.13 ± 0.90	10.94 ± 0.93	11.04 ± 0.97
End of treatment	9.88 ± 0.90	9.84 ± 0.93	10.12 ± 0.97
LS mean difference from baseline	−1.25 ± 0.38	−1.11 ± 0.28	−0.91 ± 0.21
p value	0.0040	0.0009	0.0004
Fasting plasma GLP-1 Active (pmol/l)
Baseline	3.79 ± 1.16	3.93 ± 1.19	4.73 ± 1.31
End of treatment	6.32 ± 1.16	5.10 ± 1.19	6.62 ± 1.31
LS mean difference from baseline	2.53 ± 0.83	1.17 ± 0.54	1.89 ± 0.45
p value	0.0067	0.0444	0.0005
Fasting total plasma PYY (pg/ml)
Baseline	59.30 ± 9.67	57.50 ± 7.92	53.14 ± 10.81
End of treatment	95.05 ± 9.67	75.36 ± 7.92	91.80 ± 10.81
LS mean difference from baseline	35.75 ± 6.30	17.87 ± 6.07	38.66 ± 9.89
p value	<0.0001	0.0087	0.0010

Data are the LS mean ± SEM for the evaluable population